Logo image of TVGN

TEVOGEN BIO HOLDINGS INC (TVGN) Stock Fundamental Analysis

USA - NASDAQ:TVGN - US88165K1016 - Common Stock

0.8478 USD
+0.01 (+0.68%)
Last: 9/16/2025, 3:01:25 PM
Fundamental Rating

1

Overall TVGN gets a fundamental rating of 1 out of 10. We evaluated TVGN against 540 industry peers in the Biotechnology industry. TVGN may be in some trouble as it scores bad on both profitability and health. TVGN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TVGN had positive earnings in the past year.
In the past year TVGN has reported a negative cash flow from operations.
TVGN Yearly Net Income VS EBIT VS OCF VS FCFTVGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2021 2022 2023 0 2M -2M 4M

1.2 Ratios

TVGN's Return On Assets of 337.72% is amongst the best of the industry. TVGN outperforms 99.81% of its industry peers.
TVGN's Return On Invested Capital of 14.78% is amongst the best of the industry. TVGN outperforms 95.93% of its industry peers.
Industry RankSector Rank
ROA 337.72%
ROE N/A
ROIC 14.78%
ROA(3y)0.28%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TVGN Yearly ROA, ROE, ROICTVGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2021 2022 2023 0 5 -5 -10

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TVGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TVGN Yearly Profit, Operating, Gross MarginsTVGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, TVGN has more shares outstanding
Compared to 1 year ago, TVGN has a worse debt to assets ratio.
TVGN Yearly Shares OutstandingTVGN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 50M 100M 150M
TVGN Yearly Total Debt VS Total AssetsTVGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 4.56 indicates that TVGN is not in any danger for bankruptcy at the moment.
TVGN has a better Altman-Z score (4.56) than 74.81% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 4.56
ROIC/WACCN/A
WACCN/A
TVGN Yearly LT Debt VS Equity VS FCFTVGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

TVGN has a Current Ratio of 0.12. This is a bad value and indicates that TVGN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of TVGN (0.12) is worse than 96.85% of its industry peers.
A Quick Ratio of 0.12 indicates that TVGN may have some problems paying its short term obligations.
TVGN has a worse Quick ratio (0.12) than 96.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.12
TVGN Yearly Current Assets VS Current LiabilitesTVGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 1M 2M 3M

More info and screens

1

3. Growth

3.1 Past

TVGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 375.00%, which is quite impressive.
EPS 1Y (TTM)375%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%640%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 2.23, the valuation of TVGN can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of TVGN indicates a rather cheap valuation: TVGN is cheaper than 98.89% of the companies listed in the same industry.
TVGN is valuated cheaply when we compare the Price/Earnings ratio to 27.27, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 2.23
Fwd PE N/A
TVGN Price Earnings VS Forward Price EarningsTVGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVGN Per share dataTVGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TVGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEVOGEN BIO HOLDINGS INC

NASDAQ:TVGN (9/16/2025, 3:01:25 PM)

0.8478

+0.01 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14
Earnings (Next)11-10 2025-11-10
Inst Owners2.19%
Inst Owner Change25.88%
Ins Owners84.65%
Ins Owner Change5.43%
Market Cap166.77M
Analysts82.86
Price Target10.2 (1103.11%)
Short Float %7.37%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)40.85%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 2.23
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.38
EY44.82%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 337.72%
ROE N/A
ROCE 20.88%
ROIC 14.78%
ROICexc 14.78%
ROICexgc 14.78%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)0.28%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.12
Altman-Z 4.56
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)375%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%640%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y408.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-525.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-525.64%
OCF growth 3YN/A
OCF growth 5YN/A